TRADE POLICY | 2026-08-01

Section 232 Pharmaceutical Tariffs Begin: California Guide

On July 31, 2026, the 100 percent Section 232 tariff imposed by Proclamation 11020 of April 2, 2026 took effect for patented pharmaceutical products and associated active pharmaceutical ingredients imported by the large pharmaceutical companies listed in Annex III — with a tiered relief structure offering a 20 percent rate under Commerce-approved onshoring agreements, a zero rate through January 20, 2029 for companies that also sign most-favored-nation pricing agreements with HHS, 15 and 10 percent ceilings for trade-framework partners, and a September 29, 2026 effective date for all other importers — creating immediate entry, classification, and valuation consequences for California biotech hubs and pharmaceutical supply chains.

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

On July 31, 2026, the United States began collecting Section 232 tariffs of up to 100 percent on imported patented pharmaceutical products and their associated active pharmaceutical ingredients. The duties flow from Proclamation 11020, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the Unite

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301